Tianjin Lisheng Pharmaceutical Co.,Ltd. (SHE:002393)
China flag China · Delayed Price · Currency is CNY
16.81
-0.10 (-0.59%)
Apr 29, 2026, 3:04 PM CST

SHE:002393 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
1,3511,3891,3321,1451,1411,087
Other Revenue
3.363.364.017.76.054.67
1,3541,3921,3361,1531,1471,092
Revenue Growth (YoY)
0.99%4.18%15.88%0.56%5.00%-4.29%
Cost of Revenue
638.13644.93624.04487.97510.51473.95
Gross Profit
716.32747.08712.11665.06636.08618
Selling, General & Admin
485.5520.47500.39424.61448.45466.29
Research & Development
102.15112.93122.1102.48102.26100.82
Other Operating Expenses
20.1720.6220.1919.6424.122.33
Operating Expenses
607.43653.62642.7546.47575.03589.34
Operating Income
108.8993.4669.41118.661.0528.66
Interest Expense
-2.25-2.25-2.66-0.75-0.88-0.32
Interest & Investment Income
378.51376.29147.3176.0391.93106.85
Currency Exchange Gain (Loss)
-0.02-0.020.010.010.11-0.06
Other Non Operating Income (Expenses)
-23.25-0.16-0.72.23-2.16-0.18
EBT Excluding Unusual Items
461.87467.32213.37196.12150.05134.95
Merger & Restructuring Charges
----4.99--
Gain (Loss) on Sale of Investments
2.452.112.90.620.28-
Gain (Loss) on Sale of Assets
0.30.25-0.1238.7-34.82-
Asset Writedown
-4.08-4.08-0.3-15.27-1.2-1.61
Other Unusual Items
-9.99-9.990.075.024.053.78
Pretax Income
450.55455.61215.95420.21118.36137.12
Income Tax Expense
31.3332.8829.9958.3924.7615.01
Earnings From Continuing Operations
419.22422.73185.96361.8393.61122.11
Minority Interest in Earnings
-6.33-6.44-1.43---
Net Income
412.89416.28184.53361.8393.61122.11
Net Income to Common
412.89416.28184.53361.8393.61122.11
Net Income Growth
128.56%125.59%-49.00%286.54%-23.34%1317.31%
Shares Outstanding (Basic)
307308308310308306
Shares Outstanding (Diluted)
307308308310308306
Shares Change (YoY)
-0.70%0.26%-0.83%0.59%0.70%5.91%
EPS (Basic)
1.341.350.601.170.300.40
EPS (Diluted)
1.341.350.601.170.300.40
EPS Growth
130.17%125.00%-48.57%284.29%-23.87%1238.26%
Free Cash Flow
214.7210.0434.51138.29290.47108.1
Free Cash Flow Per Share
0.700.680.110.450.940.35
Dividend Per Share
0.7500.7500.2920.3570.1790.179
Dividend Growth
157.11%157.11%-18.31%99.94%-200.17%
Gross Margin
52.89%53.67%53.30%57.68%55.48%56.60%
Operating Margin
8.04%6.71%5.20%10.29%5.32%2.62%
Profit Margin
30.48%29.90%13.81%31.38%8.16%11.18%
Free Cash Flow Margin
15.85%15.09%2.58%11.99%25.33%9.90%
EBITDA
181.28167.03147.7185.03126.2587.94
EBITDA Margin
13.38%12.00%11.05%16.05%11.01%8.05%
D&A For EBITDA
72.3973.5778.2966.4365.259.28
EBIT
108.8993.4669.41118.661.0528.66
EBIT Margin
8.04%6.71%5.20%10.29%5.32%2.62%
Effective Tax Rate
6.95%7.22%13.89%13.89%20.92%10.95%
Revenue as Reported
1,3921,3921,3361,1531,1471,092
Advertising Expenses
-247.48266.99253.43264.36283.37
Source: S&P Global Market Intelligence. Standard template. Financial Sources.